New Pharmaceuticals Industry GBI Research Reports Available at MarketPublishers.com
01 Dec 2011 • by Natalie Aster
Market Publishers Ltd informs that new GBI Research's Pharmaceuticals Industry reports have been added to its catalogue:
The global central nervous system (CNS) disorder therapeutics market is valued as $53.1 billion in 2010, grew from $36.8 billion in 2002 with a Compound Annual Growth Rate (CAGR) of 4.7%.The product pipeline of the CNS disorder therapeutics market is promising, with many novel molecules at various stages of development, some with disease-modifying characteristics. The anticipated launch of late stage and novel molecules is expected to fulfill the unmet needs and drive the growth of the global CNS disorders therapeutics market in upcoming years.
The product pipeline for multiple sclerosis (MS) has many orally administered novel molecules, and for Alzheimer’s disease the product pipeline has novel molecules such as bapineuzumab, solanezumab and BMS-708163 which target the underlying causes of the disease and thus may offer significant clinical benefits to the patients. The market for schizophrenia and bipolar disorder therapeutics is estimated to be driven by the anticipated launch of AZ-004 and other molecules such as cariprazine, zicronapine, and RG-1678 and aripiprazole depot injection.
GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing
G-Protein-Coupled Receptors (GPCR) are the Most Diverse Type of Receptors in the Human Body. The understanding of GPCR biology was limited for a very long time, although researchers were successful in identifying many GPCR targets using genomic approaches. However, there was no real understanding of the receptor structure-function relationship, and how different signaling molecules activated these receptors. Hence, the goal was to find the endogenous and/or exogenous ligands that paired with each GPCR, which could help the discovery of new avenues in therapy and de-orphanization of GPCRs. However, there are still more than 100 orphan GPCRs for which ligands have not yet been identified. This coupled with the fact that only about 30% of the 800 odd GPCRs have been targeted so far by currently marketed medicines leads to the conclusion that GPCR research has immense potential to bring out new therapies.
Published: November'11
Report Price: $3500 (Single User License)
More new market research reports by GBI Research can be found at publisher page.
To order the report or ask for sample pages contact [email protected]
Contacts
MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com
Analytics & News
